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Purpose: To prospectively evaluate hepatic extracellular volume 
(ECV) fraction measurement at equilibrium computed 
tomographic (CT) imaging compared with both fibrosis 
quantified with histologic analysis and the enhanced liver 
fibrosis panel (ELF) in a cohort of patients with chronic 
hepatitis.
Materials and 
Methods:
This prospective study was approved by the regional 
ethics committee. All patients gave fully informed writ-
ten consent. Forty patients with a clinical indication for 
liver biopsy were prospectively recruited for liver ECV 
quantitation at equilibrium CT imaging. Biopsy samples 
underwent digital image analysis and assessment of colla-
gen content expressed as the collagen-proportionate area 
(CPA). Spearman correlation was used to evaluate asso-
ciation between ECV, ELF, and CPA. Multiple regression 
analysis was used to test prediction of CPA by a model 
that combined ECV and ELF. ECV, ELF score, and CPA 
were compared with Ishak stage by using the Kruskal-
Wallis test.
Results: Complete ECV, ELF, and CPA were available in 33 pa-
tients. Liver ECV, CPA, and ELF had a median of 0.26 (in-
terquartile range [IQR], 0.24–0.29), 5.0 (IQR, 3.0–15.0), 
and 9.71 (IQR, 8.14–10.92), respectively. Hepatic ECV 
demonstrated good association with CPA (r = 0.64; P , 
.001) and ELF score (r = 0.38; P , .027), with no signifi-
cant difference in strength of correlation (P = .177). The 
regression model that combined ELF and ECV achieved 
good prediction of CPA (R2 = 0.67; P , .001). Significant 
variation in ECV and ELF was seen between fibrosis stage 
groups.
Conclusion: Hepatic ECV measured with equilibrium CT imaging is 
associated with biopsy-derived CPA and serum ELF-vali-
dated markers of liver fibrosis. This suggests that equilib-
rium CT imaging can quantify diffuse fibrosis in chronic 
liver disease.
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biopsy, and provision of written informed 
consent for study participation. Exclusion 
criteria were contraindication to contrast 
agent–enhanced CT (iodinated contrast 
agent allergy and estimated glomerular 
filtration rate , 60 mL/min) or human 
immunodeficiency virus coinfection, pre-
vious liver transplantation, or a history of 
significant alcohol consumption (>32 g of 
alcohol per day for men; >24 g of alcohol 
per for women). There were 190 patients 
identified who met inclusion criteria. Of 
these, 32 patients were human immuno-
deficiency virus positive, 22 patients had 
a history of liver transplantation, 28 pa-
tients had impaired renal function, three 
patients reported an iodine allergy, and 
65 patients had a history of significant 
alcohol consumption. In total, 40 patients 
fully met the inclusion and exclusion 
criteria.
Histologic Analysis
Liver biopsies were performed accord-
ing to local guidelines as part of the rou-
tine clinical care of the patient. Percuta-
neous biopsy was performed by using a 
Menghini technique (19) with a 16-gauge 
needle from the right lobe. Transjugu-
lar biopsy samples were collected with 
up to four passes of a 19-gauge needle 
through either the right or middle he-
patic vein wall (20).
Chronic liver disease is a public health issue (1), and there were an estimated 1.29 million deaths 
worldwide in 2010 from viral hepatitis 
alone (2). Regardless of its etiologic 
cause, sustained liver injury eventually 
leads to diffuse interstitial fibrosis and 
expansion of the extracellular space by 
collagenous scar that distorts the normal 
architecture, impairs hepatic function, 
and is the hallmark of cirrhosis. Evalu-
ation of hepatic fibrosis plays a key role 
in disease management by facilitating 
prognostication and guiding therapies, 
such as antiviral agents, which in some 
instances may reverse the fibrogenic 
process (3). Histopathologic evaluation 
of biopsy samples remains the reference 
standard test for assessment of diffuse 
hepatic fibrosis, but it has a number of 
well-documented limitations, including 
its invasive nature and associated small 
but significant risk of complications (4). 
Furthermore, it examines only a tiny 
fraction of the organ (5) and is there-
fore prone to sampling error (6). These 
deficiencies have fueled the development 
of noninvasive techniques for fibrosis 
quantification. Liver stiffness measure-
ment with transient elastography is well 
validated (7), but requires dedicated 
equipment and is of limited use in obese 
patients and those with ascites or nar-
row intercostal spaces (8). Serum bio-
markers, such as the enhanced liver fi-
brosis (ELF) test, are sufficiently related 
to liver fibrosis to be clinically useful (9), 
but they are not liver specific (10), and 
some have other influences, such as re-
nal function, that reduce their discrim-
ination between mild and moderate fi-
brosis (11,12).
Equilibrium imaging is a technique 
that uses contrast agents already used 
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cohort of patients with chronic 
viral hepatitis.
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widely in computed tomographic (CT) 
and magnetic resonance (MR) imaging 
to evaluate the fractional extracellular 
volume (ECV) that is expanded in fi-
brosis and other deposition processes, 
such as amyloidosis. The technique with 
both MR imaging and CT has been ap-
plied successfully to quantify myocardial 
ECV (13–15) as a surrogate marker 
for diffuse fibrosis. The technique was 
also applied to the liver by using MR 
imaging to quantify amyloid deposition 
(16). Intuitively, the technique may 
have a role in assessment of diffuse 
liver fibrosis, and Varenika et al (17) 
recently described a strong correlation 
between hepatic ECV and histologic fi-
brosis area in a rodent model of chronic 
liver disease. Early retrospective studies 
(18) suggest that this observation may 
translate to humans. To our knowledge, 
there was no validation of equilibrium 
imaging assessment of diffuse liver fibro-
sis compared with a histopathologic ref-
erence and, in particular, a robust mor-
phometric quantitation of collagen in an 
appropriate spectrum of patients with a 
range of disease severity.
The purpose of this initial explor-
atory study is to prospectively evaluate 
hepatic ECV measurement by equilib-
rium CT imaging compared with both 
fibrosis that was quantified with histo-
logic analysis and the ELF panel (9) in a 
cohort of patients with chronic hepatitis.
Materials and Methods
This prospective study was approved by 
the regional ethics committee (reference 
number 09/H0716/75). All patients gave 
fully informed written consent.
Patients were recruited between April 
2011 and July 2013 from the chronic liver 
disease outpatient service at a single ter-
tiary referral center (Royal Free Univer-
sity Hospital, Hampstead, England). Inclu-
sion criteria were serologically confirmed 
hepatitis B or C, clinically indicated liver 
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To ensure reliable histopathologic 
evaluation, we only included biopsy 
samples that were 12 mm or greater 
in length (21). Samples were formalin 
fixed, paraffin embedded, and stained 
with hematoxylin and eosin and Gor-
don and Sweet staining for reticulin. 
Fibrosis stage was recorded by an ex-
perienced hepatopathologist accord-
ing to the Ishak system (22). A further 
tissue section was stained with picro-
Sirius red for collagen-proportionate 
area (CPA) quantification by digital 
image analysis. Digital image analysis 
was performed independent of fibro-
sis staging by a single operator (A.H.) 
with the method described by Calvar-
uso et al (23). A digital camera (Pow-
ershot A640; Canon U.S.A., Melville, 
NY) on the macro setting was used for 
low-magnification whole-section image 
capture. Digital image analysis was per-
formed by using software (Zeiss KS300; 
Carl Zeiss Microscopy, Jena, Germany) 
and included steps to eliminate image 
artifacts and structural collagen in por-
tal tracts and blood vessel walls. White 
space within natural structures, such as 
vascular cavities, was not included.
Equilibrium Contrast-enhanced CT 
Imaging
The principal of equilibrium imaging 
is that contrast agents are exclusively 
extracellular tracers, and, once they 
are administered, they passively pass 
from the blood plasma (intravascular 
compartment) into the interstitium 
(extravascular extracellular compart-
ment), but do no not cross cell mem-
branes to enter the cells. During the 
equilibrium phase after administration 
of the contrast agent, the concentra-
tion of contrast agent within the intra-
vascular compartment is approximately 
equal to that within the extravascular 
extracellular compartment. The frac-
tional volume of the extracellular space 
within a tissue can then be quantified 
by measuring the relative enhancement 
of the tissue compared with blood and 
multiplying by the ECV of blood (1 2 
hematocrit) (15).
In this initial exploratory study, 
a steady-state contrast agent equilib-
rium protocol (24) was used based on 
a bolus injection of contrast agent, fol-
lowed by an infusion. This method was 
chosen to minimize potential error that 
could result from intersubject hemody-
namic or contrast agent kinetics varia-
tion that could arise from a single bolus 
technique (13).
Equilibrium CT imaging was per-
formed with a 64–detector row CT 
scanner (Somatom Sensation 64; Sie-
mens Medical Solutions, Erlangen, 
Germany) no more than 2 weeks be-
fore liver biopsy. Before CT examina-
tion, two 5-mL blood samples were col-
lected. The first was sent for complete 
blood count to obtain blood hematocrit, 
and the second for ELF analysis.
A scan before administration of the 
contrast agent was acquired through the 
upper abdomen to include the whole 
liver with the following parameters: ef-
fective tube current-time product, 250 
mAs; pitch, 0.8; tube voltage, 120 kV; 
section collimation, 24 mm 3 1.2 mm; 
gantry rotation time, 500 msec; recon-
structed to a section thickness of 10 mm 
with a soft-tissue convolution kernel 
(B20f). The iodinated contrast agent io-
hexol (Omnipaque 300; GE Healthcare, 
Cork, Ireland) was then administered as 
a bolus dose of 1 mL/kg at 3 mL/sec; 
followed immediately by an infusion of 
1.88 mL/kg per hour based on previ-
ous development work (24) that dem-
onstrated contrast agent steady state 
on sequential plasma iohexol measure-
ments and CT scan attenuation mea-
surements. Mean total contrast agent 
volume administered across the cohort 
was 152 mL 6 28 (standard deviation). 
After 30 minutes of infusion, the scan 
volume through the upper abdomen 
was repeated with the same parame-
ters. Size-specific dose estimates were 
derived by using scanner-calculated vol-
ume CT dose index, and patient antero-
posterior and lateral dimensions were 
measured from the CT series obtained 
before administration of contrast agent 
at the midliver level (25).
Image analysis was performed with 
software (OsiriX v4.1.2; OsiriX Foun-
dation, Geneva, Switzerland) by a radi-
ologist (S.B., with 8 years of experience 
interpreting body CT scans) who was 
blinded to biopsy findings.
On three contiguous sections re-
constructed to a thickness of 10 mm, 
a peripherally based wedge-shaped re-
gion of interest was drawn in segment 
VII of the liver (mean area, 34.5 cm2) 
to include the greatest area of liver pa-
renchyma while avoiding visible vessels 
or incidental hepatic lesions, such as 
cysts. Because the exact liver segment 
from which the biopsy samples were 
collected was not known in all cases, im-
aging biopsy matching was at the level 
of the right lobe only. A further ellip-
tical region of interest was drawn on 
the same section within the abdominal 
aorta (mean area, 1.6 cm2) by avoiding 
the aortic wall and any atheromatous 
plaque. Because of the possible uptake 
of iodinated contrast agent into hepa-
tocytes and vicarious excretion into the 
biliary system, regions of interest (mean 
area, 2.8 cm2) were also placed in the 
gallbladder lumen, when present, with 
visible calcified gallstones avoided. All 
regions of interest were drawn on the 
images that were obtained after contrast 
agent administration and then copied to 
the matching sections on the images that 
were obtained before contrast agent ad-
ministration (Fig 1). Mean attenuation 
(in Hounsfield units) for liver paren-
chyma, gall bladder, and blood was de-
rived and liver ECV calculated by using 
the following formula:
ECVliver = (1 2 hematocrit)  
       3 (HUliver/HUblood),
where HU are Hounsfield units in equi-
librium phase minus Hounsfield units 
before contrast agent administration.
ELF Test Biomarker
Patient serum was separated from 
blood collected before the CT exami-
nation and stored at 280°C before it 
was sent to an independent laboratory 
(iQur Limited, London, England). Pro-
prietary assays (Siemens Healthcare 
Diagnostics, Tarrytown, NY) were used 
in conjunction with an automated ana-
lyzer (Advia Centaur; Siemens Health-
care Diagnostics) in accordance with 
the instructions from the manufacturer 
to determine levels of tissue inhibitor of 
matrix metalloproteinase 1, hyaluronic 
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acid, and amino-terminal propeptide 
of type-III collagen. Results were com-
bined by using an algorithm to generate 
a fibrosis score (9).
Statistical Analysis
Statistical analyses were performed by 
using software (Prism 5.0; Graphpad, 
San Diego, Calif). Kolmogorov-Smirnov 
analysis was used to test for normality. 
Non-Gaussian distributed data were ex-
pressed as a median and interquartile 
range. Correlation between variables 
was evaluated by using Spearman cor-
relation, with one-sided significance 
testing (set to P  .05), and Fisher 
r-to-z transformation to assess the sig-
nificance of the difference between cor-
relation coefficients. Linear regression 
was used to evaluate the ability of ECV, 
ELF, and a model that combined ECV 
and ELF scores to predict CPA. The R 
and R2 values were used to assess the 
strength of correlation, and P values 
less than .05 were considered to indi-
cate a significant difference.
Histologic stage was divided into 
low (S0–S1), moderate (S2–S4), and 
severe (S5–S6) groups, and ECV, CPA, 
and ELF scores were compared with fi-
brosis stage by using the Kruskal-Wallis 
nonparametric analysis of variance test.
A paired t test was used to assess 
for an increase in attenuation within 
the lumen of the gallbladder between 
the before-equilibrium and equilibrium-
phase images.
Results
Among the 40 patients who fulfilled the 
eligibility criteria, complete sets of data 
(ECV, CPA, and ELF score) were col-
lected in 33 cases (four histologic sam-
ples were fragmented or measured less 
than 12 mm; two patients had estimated 
glomerular filtration rates of ,60 mL/
min before undergoing CT examination; 
and one patient withdrew consent). 
Among the 33 patients, a diagnosis of 
hepatitis C virus infection was obtained 
in 23 cases and a diagnosis of hepatitis 
B was obtained in 10. We collected 24 
tissue samples by ultrasonographically 
guided biopsy and nine tissue samples 
by transjugular biopsy. Demographic and 
ELF details are summarized in the Table.
Equilibrium CT examination size-
specific dose estimate had a mean 
value of 38.8 mGy 6 8.2. The region-
of-interest volume was approximately 
500 times as large as that of the av-
erage of each biopsy (10.4 mL vs 0.02 
mL). The mean attenuation within the 
liver and aorta before contrast agent 
administration was 50 HU (range, 24–
62 HU) and 41 HU (range, 32–51 HU), 
respectively; and at equilibrium phase 
was 67 HU (range, 38–78 HU) and 80 
HU (range, 71–94 HU), respectively.
The gallbladder was present in 24 
of the 33 patients analyzed, and mean 
attenuation within the gallbladder lu-
men was 9 HU (range, 2–25 HU) be-
fore contrast agent administration and 
Summary of Demographic and 
Clinical Data
Parameter Result
No. of patients 33 
 Men 19
 Women 14
Mean age (y) 49.9
 Men 48.8
 Women 51.4
Age range (y) 22–68
 Men 22–68
 Women 27–66
Biopsy method
 Transcutaneous 25
 Transjugular 8
Mean hematocrit* 0.428 6 0.041
Mean serum creatinine  
 concentration (mmol/L)*
89.5 6 22
Mean international  
 normalized ratio*
1.22 6 0.42
Mean bilirubin (mmol/L)* 16.6 6 10.6
*Data are 6 standard deviation.
Figure 1
Figure 1:  Equilibrium CT and biopsy specimen (picro-Sirius red stain; macro view) images from a patients 
with, A, no significant fibrosis (ECV = 0.21; CPA = 3) and, B, severe fibrosis (ECV = 0.31; CPA = 24). 
Sampled volumes between equilibrium (EQ) CT and biopsy differ by magnification of approximately 31500. 
Note that the inferior vena cava and right portal vein branches in, B, are less visible than in, A, because ECV 
of liver is similar to that of the blood.
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11 HU (range, 2–24 HU) after contrast 
agent administration. Paired t test con-
firmed no significant difference (P = 
.08) in gallbladder lumen attenuation 
between the before contrast agent ad-
ministration and equilibrium-phase im-
ages (mean difference, 1.1 HU).
Median fractional ECV measured in 
the liver was 0.26 (interquartile range 
[IQR], 0.24–0.29; range, 0.17–0.47); 
median CPA was 5.0 (IQR, 3.0–15.0; 
range, 1.8–28.3); and median ELF 
score was 9.71 (IQR, 8.14–10.92; 
range, 7.27–12.43).
Fractional ECV showed good asso-
ciation with CPA (r = 0.64; P , .001) 
and ELF score (r = 0.38; P , .027) 
(Fig 2, A, B), with no significant differ-
ence in the strength of the correlations 
(P = .177). A significant association was 
also found between ELF score and CPA 
(r = 0.46; P , .007) (Fig 2, C).
Multiple regression analysis showed 
that both ECV (P , .001) and ELF (P , 
.006) were significant independent pre-
dictors of CPA, with a t statistic for ECV 
and ELF of 5.20 and 2.94, respectively. 
The regression model (80 3 ECV + 1.8 
3 ELF 2 30.4) was a better predictor 
of CPA (R2 = 0.67; P , .001) (Fig 2, D) 
than either ECV (R2 = 0.56; P , .001) or 
ELF (R2 = 0.35; P , .017) alone.
ECV, ELF, and CPA demonstrated 
comparable discrimination between 
Ishak score of S0–S1 versus S5–S6 
and S2–S4 versus S5–S6 (P , .013, 
P , .016, and P , .001, respectively) 
(Fig 3, A–C). None of the three was 
able to significantly distinguish S0–S1 
and S2–S4 (P . .05).
Discussion
In this prospective initial exploratory 
study, we measured ECV by using equi-
librium contrast agent CT examination. 
We found that ECV tracked liver fibro-
sis, measured either by CPA or by Ishak 
fibrosis stage. These results are consis-
tent with preliminary studies (17) that 
use animal models, and they tentatively 
suggest that a CT examination per-
formed with widely available equipment 
and contrast agents could be used to 
evaluate hepatic fibrosis, which would 
reduce the need for invasive biopsy.
We used automated morphometric 
fibrosis quantification as our primary 
histologic comparator. As a continuous 
measurement, this largely eliminated 
limitations of traditional categorical 
staging. Data suggest that CPA is a bet-
ter predictor of future clinical decom-
pensation than Ishak stage (26), which 
shows strong correlation with hepatic 
venous pressure gradient (a good prog-
nostic index in relation to survival and 
complications) (27). However, CPA is 
limited by biopsy, with accuracy depen-
dent on etiologic origin of cirrhosis and 
biopsy specimen size (21).
We also compared equilibrium CT 
examination–derived ECV with a bio-
chemical marker: the ELF test. The 
ELF score is a well-validated marker of 
hepatic fibrosis that incorporates levels 
of extracellular matrix components and 
enzymes involved in their regulation, 
and it is a strong predictor of clinical 
outcome in chronic liver disease (28). 
Previous work showed association 
between ELF score and histologic fi-
brosis stage, and this was confirmed by 
our current study. ECV correlated with 
ELF, which suggested that ECV does 
reflect underlying damage and fibro-
sis, although the strength of associa-
tion was lower than with CPA. Neither 
ECV nor ELF has the limitations of 
histologic staging and CPA, which are 
imposed by reliance on liver biopsy. It 
may be that their ability to sample the 
whole liver volume reduces sampling 
error and may improve repeatability. 
Although we primarily used ELF to test 
the ability of equilibrium CT imaging 
to estimate liver fibrosis, regression 
analysis showed them to be indepen-
dent predictors of CPA, and when ELF 
and ECV were combined they better 
predicted CPA than either in isolation. 
The combination of two noninvasive 
tests to accurately predict liver fibro-
sis is clearly an attractive proposition 
and validation in a new cohort is now 
required.
Figure 2
Figure 2: Scatterplots show correlations between ECV measured by using equilibrium CT, A, histologic 
CPA and, B, ELF score, and, C, correlation between ELF and CPA, with lines of best fit. D, Multiple regression 
model combines EVC and ELF score to predict CPA.
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Recent use of equilibrium imaging 
by several groups provided good evi-
dence for an association between el-
evated ECV and diffuse fibrosis in the 
heart (13,15,29), and amyloid protein 
deposition in the heart, liver, and spleen 
(16,14). There are, however, limita-
tions of equilibrium imaging for fibrosis 
assessment. The principle behind its 
use is that accumulation of extracellu-
lar collagenous matrix is accompanied 
by expansion in the extracellular water 
into which contrast agents distribute. 
There are several other processes that 
may affect this volume and confound 
fibrosis measurement. Edema from 
inflammation or venous congestion, 
for example, may expand ECV, while 
hepatocellular swelling from steatosis 
may compress the ECV. A further im-
portant point to emphasize is that the 
ECV includes the ECV in the whole tis-
sue (parenchyma and enclosed vascula-
ture); in other words, both interstitial 
fluid and the interstitial (plasma) blood 
compartment. This is small in tissues 
like myocardium, but much larger and 
potentially independently varying with 
disease in the liver. A further potential 
confounder in the liver is the vicarious 
uptake of contrast agents by hepato-
cytes that occurs after delayed contrast 
agent administration. This phenom-
enon is thought to be associated with 
impaired renal function, but has been 
described in patients with normal kid-
neys (30). Contrast agent uptake by he-
patocytes and excretion via the biliary 
tree would lead to increased hepatic 
enhancement relative to blood and an 
overestimation of liver ECV. The lack 
of a discernible increase in the attenu-
ation of bile in the gallbladder suggests 
that in this small group, significant vi-
carious excretion had not occurred 
after the 30-minute infusion. It should 
be noted that patients with major re-
nal impairment were excluded from the 
study, which therefore lessened the risk 
of confounding the fractional hepatic 
ECV estimates by vicarious excretion.
We used standard CT image acqui-
sition and reconstruction techniques, 
which are widely available. Modern 
multidetector scanners and reconstruc-
tion techniques may reduce image arti-
facts and noise, leading to more precise 
and accurate ECV quantitation while 
reducing the dose of ionizing radiation 
(31,32). Mean size-specific dose esti-
mate for liver equilibrium CT exami-
nation in this study was comparable to 
that of a standard clinical CT examina-
tion of the liver and equivalent to 3.5 
years of natural background radiation 
in the United States (33). The theoret-
ical risk associated with this exposure 
(34) needs to be weighed against the 
sampling error and complication risks 
associated with biopsy and operator 
dependence and patient-limiting factors 
associated with transient elastographic 
imaging.
The reference steady-state equilib-
rium method used in this study involves 
establishing a constant plasma concen-
tration of contrast agent via a prolonged 
infusion. Although time consuming and 
somewhat impractical, at the time of 
the study design, it was considered the 
most robust method. A further limita-
tion of the infusion technique is the rel-
atively low level of enhancement within 
the aorta and liver during the delayed 
equilibrium phase. Even with large re-
gions of interest, the contrast-to-noise 
ratio at this level of enhancement is 
relatively low. Recently validated equi-
librium contrast agent protocols used 
rapid-bolus-only methods (35) that, for 
tissues with rapid kinetics (ie, the myo-
cardium), produces a dynamic equilib-
rium of changing but related plasma and 
interstitial contrast agent concentra-
tions and may be of sufficient accuracy 
to replace less practicable protocols 
that use prolonged infusions. Several 
groups used this method by imaging be-
fore and 7–10 minutes after a standard 
clinical bolus of contrast material (13), 
which demonstrated higher contrast-
to-noise ratio and good approximation 
of ECV within the myocardium. By us-
ing a bolus and infusion technique, we 
ensured equilibrium; however, our cur-
rent studies now use this simpler so-
called bolus-only technique that allows 
the whole scan to be performed in 10 
minutes. Simple integration of whole-
liver ECV quantitation into clinical CT 
examination, which supplements ana-
tomic assessment and focal lesion de-
tection, is clearly desirable and a future 
study is now indicated.
There were additional limitations 
to our study. Our patient selection re-
sulted in a relatively high proportion 
of patients with mild fibrosis: 70% of 
our patient cohort had CPA values clus-
tered between 2 and 8.1. Future studies 
Figure 3
Figure 3: Box-and-whisker plots include median and 25th and 75th percentiles and show, A, ECV, B, CPA and, C, ELF score by Ishak fibrosis stage. ∗P = .01–.05, 
∗∗P = .001–.01, ∗∗∗P , .001.
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should endeavor to recruit a patient 
cohort equally distributed across the 
range of fibrosis severity. We used a 
single etiologic origin of virally induced 
hepatitis to ensure homogeneity in our 
data. However, we cannot assume the 
results can be extrapolated to other dis-
easess, such as alcoholic liver disease 
and nonalcohoic fatty liver disease.
Factors thought to affect hepatic 
extracellular volume fraction, such as 
hepatic inflammation, steatosis, hepatic 
venous congestion, and portal venous 
flow, were not controlled for in this 
study, and future studies may examine 
the influence of these confounders on 
hepatic ECV.
Although a comparison is made here 
with the current reference standard of 
histologic analysis, we did not include 
other techniques that showed strong 
association with clinical markers of 
liver cirrhosis. Hepatic venous pressure 
gradient and transient elastography are 
both well validated by comparison with 
histologic analysis and are predictive of 
decompensation and portal hyperten-
sion–related complications (36). Future 
studies should include comparison of 
ECV with liver stiffness measurement 
and hepatic venous pressure gradient.
This study provides biopsy-con-
trolled evidence for a relationship be-
tween ECV and diffuse liver fibrosis in 
humans and provides basis for a larger 
study to examine the diagnostic perfor-
mance of equilibrium imaging for non-
invasive monitoring of liver disease se-
verity. Combination of two noninvasive 
tests (ECV measured with equilibrium 
CT imaging and ELF) to accurately 
predict liver fibrosis is potentially pow-
erful, and validation studies are now 
indicated.
Acknowledgments: The authors acknowledge 
the help given to this study by Alison Winstan-
ley, MBBS, BS, MRCPath; Gemma Lewis, BS; 
and Priti Dutta.
Disclosures of Conflicts of Interest: S.B. dis-
closed no relevant relationships. S.P. disclosed 
no relevant relationships. W.M.R. Activities re-
lated to the present article: disclosed no rele-
vant relationships. Activities not related to the 
present article: author reports personal fees 
from Siemens Healthcare Diagnostics. Other 
relationships: disclosed no relevant relation-
ships. R.J. Activities related to the present 
article: disclosed no relevant relationships. 
Activities not related to the present article: 
reports fees paid to his institution from Oc-
era Therapeutics for consultancy and patents, 
Grifols for grants/grants pending, and Norgine 
for lectures. Other relationships: disclosed no 
relevant relationships. A.R.H. disclosed no rel-
evant relationships. A.P. disclosed no relevant 
relationships. J.C.M. disclosed no relevant re-
lationships. S.A.T. Activities related to the pre-
sent article: disclosed no relevant relationships. 
Activities not related to the present article: re-
ports personal fees from research consultancy 
to Robarts. Other relationships: disclosed no 
relevant relationships.
References
 1. Bosetti C, Levi F, Lucchini F, Zatonski WA, 
Negri E, La Vecchia C. Worldwide mor-
tality from cirrhosis: an update to 2002. J 
Hepatol 2007;46(5):827–839.
 2. Cowie BC, Carville KS, MacLachlan JH. 
Mortality due to viral hepatitis in the 
Global Burden of Disease Study 2010: new 
evidence of an urgent global public health 
priority demanding action. Antivir Ther 
2013;18(8):953–954.
 3. Ellis EL, Mann DA. Clinical evidence for 
the regression of liver fibrosis. J Hepatol 
2012;56(5):1171–1180.
 4. Gilmore IT, Burroughs A, Murray-Lyon IM, 
Williams R, Jenkins D, Hopkins A. Indica-
tions, methods, and outcomes of percuta-
neous liver biopsy in England and Wales: 
an audit by the British Society of Gastro-
enterology and the Royal College of Physi-
cians of London. Gut 1995;36(3):437–441.
 5. Nord HJ. Biopsy diagnosis of cirrhosis: 
blind percutaneous versus guided direct 
vision techniques—a review. Gastrointest 
Endosc 1982;28(2):102–104.
 6. Regev A, Berho M, Jeffers LJ, et al. Sam-
pling error and intraobserver variation in 
liver biopsy in patients with chronic HCV 
infection. Am J Gastroenterol 2002;9 
7(10):2614–2618.
 7. Foucher J, Chanteloup E, Vergniol J, et al. 
Diagnosis of cirrhosis by transient elastog-
raphy (FibroScan): a prospective study. 
Gut 2006;55(3):403–408.
 8. Castera L. Noninvasive methods to assess 
liver disease in patients with hepatitis B 
or C. Gastroenterology 2012;142(6):1293–
1302.e4.
 9. Rosenberg WM, Voelker M, Thiel R, et al. 
Serum markers detect the presence of liver 
fibrosis: a cohort study. Gastroenterology 
2004;127(6):1704–1713.
 10. Abignano G, Cuomo G, Buch MH, et al. 
The enhanced liver fibrosis test: a clinical 
grade, validated serum test, biomarker of 
overall fibrosis in systemic sclerosis. Ann 
Rheum Dis 2014;73(2):420–427.
 11. Wahl K, Rosenberg W, Vaske B, et al. 
Biopsy-controlled liver fibrosis staging us-
ing the enhanced liver fibrosis (ELF) score 
compared to transient elastography. PLoS 
ONE 2012;7(12):e51906.
 12. Parkes J, Guha IN, Roderick P, Rosenberg 
W. Performance of serum marker panels 
for liver fibrosis in chronic hepatitis C. J 
Hepatol 2006;44(3):462–474.
 13. Nacif MS, Kawel N, Lee JJ, et al. Intersti-
tial myocardial fibrosis assessed as extra-
cellular volume fraction with low-radiation-
dose cardiac CT. Radiology 2012;264(3): 
876–883.
 14. Banypersad SM, Sado DM, Flett AS, et al. 
Quantification of myocardial extracellular 
volume fraction in systemic AL amyloid-
osis: an equilibrium contrast cardiovascu-
lar magnetic resonance study. Circ Cardio-
vasc Imaging 2013;6(1):34–39.
 15. Flett AS, Hayward MP, Ashworth MT, et 
al. Equilibrium contrast cardiovascular 
magnetic resonance for the measurement 
of diffuse myocardial fibrosis: prelimi-
nary validation in humans. Circulation 
2010;122(2):138–144.
 16. Bandula S, Banypersad SM, Sado D, et al. 
Measurement of tissue interstitial volume in 
healthy patients and those with amyloidosis 
with equilibrium contrast-enhanced MR im-
aging. Radiology 2013;268(3):858–864.
 17. Varenika V, Fu Y, Maher JJ, et al. He-
patic fibrosis: evaluation with semiquan-
titative contrast-enhanced CT. Radiology 
2013;266(1):151–158.
 18. Zissen MH, Wang ZJ, Yee J, Aslam R, 
Monto A, Yeh BM. Contrast-enhanced CT 
quantification of the hepatic fractional ex-
tracellular space: correlation with diffuse 
liver disease severity. AJR Am J Roentgen-
ol 2013;201(6):1204–1210.
 19. Menghini G. One-second biopsy of the 
liver—problems of its clinical application. 
N Engl J Med 1970;283(11):582–585.
 20. Cholongitas E, Burroughs AK. Liver: Tran-
sjugular liver biopsy yields high-quality sam-
ples. Nat Rev Gastroenterol Hepatol 2012; 
9(9):491–492.
 21. Hall AR, Tsochatzis E, Morris R, Burroughs 
AK, Dhillon AP. Sample size requirement for 
digital image analysis of collagen proportionate 
area in cirrhotic livers. Histopathology 2013; 
62(3):421–430.
Radiology: Volume 275: Number 1—April 2015 n radiology.rsna.org 143
GASTROINTESTINAL IMAGING: Equilibrium Contrast-enhanced CT Imaging to Evaluate Hepatic Fibrosis Bandula et al
 22. Knodell RG, Ishak KG, Black WC, et al. For-
mulation and application of a numerical scor-
ing system for assessing histological activity in 
asymptomatic chronic active hepatitis. Hepa-
tology 1981;1(5):431–435.
 23. Calvaruso V, Burroughs AK, Standish R, et 
al. Computer-assisted image analysis of liver 
collagen: relationship to Ishak scoring and 
hepatic venous pressure gradient. Hepatology 
2009;49(4):1236–1244.
 24. Bandula S, White SK, Flett AS, et al. Mea-
surement of myocardial extracellular volume 
fraction by using equilibrium contrast-en-
hanced CT: validation against histologic find-
ings. Radiology 2013;269(2):396–403.
 25. Christner JA, Braun NN, Jacobsen MC, 
Carter RE, Kofler JM, McCollough CH. 
Size-specific dose estimates for adult pa-
tients at CT of the torso. Radiology 2012;265 
(3):841–847.
 26. Calvaruso V, Dhillon AP, Tsochatzis E, et al. 
Liver collagen proportionate area predicts 
decompensation in patients with recurrent 
hepatitis C virus cirrhosis after liver trans-
plantation. J Gastroenterol Hepatol 2012; 
27(7):1227–1232.
 27. Armonis A, Patch D, Burroughs A. Hepatic 
venous pressure measurement: an old test as 
a new prognostic marker in cirrhosis? Hepa-
tology 1997;25(1):245–248.
 28. Parkes J, Roderick P, Harris S, et al. En-
hanced liver fibrosis test can predict clini-
cal outcomes in patients with chronic liver 
disease. Gut 2010;59(9):1245–1251.
 29. Wong TC, Piehler K, Meier CG, et al. Associ-
ation between extracellular matrix expansion 
quantified by cardiovascular magnetic reso-
nance and short-term mortality. Circulation 
2012;126(10):1206–1216.
 30. Hopper KD, Weingast G, Rudikoff J, Thick-
man D. Vicarious excretion of water-soluble 
contrast media into the gallbladder in patients 
with normal serum creatinine. Invest Radiol 
1988;23(8):604–608.
 31. Chen B, Marin D, Richard S, Husarik D, 
Nelson R, Samei E. Precision of iodine 
quantification in hepatic CT: effects of iter-
ative reconstruction with various imaging 
parameters. AJR Am J Roentgenol 2013;200 
(5):W475–W482.
 32. Shuman WP, Green DE, Busey JM, et al. 
Model-based iterative reconstruction versus 
adaptive statistical iterative reconstruction 
and filtered back projection in liver 64-MDCT: 
focal lesion detection, lesion conspicuity, 
and image noise. AJR Am J Roentgenol 
2013;200(5):1071–1076.
 33. National Council on Radiation Protection and 
Measurements. Ionizing radiation exposure of 
the population of the United States. National 
Council on Radiation Protection report no. 
160. Bethesda, Md: National Council on Ra-
diation Protection and Measurements, 2009.
 34. Hendee WR, O’Connor MK. Radiation risks 
of medical imaging: separating fact from fan-
tasy. Radiology 2012;264(2):312–321.
 35. White SK, Sado DM, Fontana M, et al. T1 
mapping for myocardial extracellular volume 
measurement by CMR: bolus only versus 
primed infusion technique. JACC Cardiovasc 
Imaging 2013;6(9):955–962.
 36. Robic MA, Procopet B, Métivier S, et al. Liver 
stiffness accurately predicts portal hyperten-
sion related complications in patients with 
chronic liver disease: a prospective study. J 
Hepatol 2011;55(5):1017–1024.
